Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

A cloud-based Software-as-a-Service platform SOPHiA DDM™ platform that enables healthcare institutions to get quick, robust insights from their data. They apply their technology to diseases such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts.

 
Get Started
Request a Quote

Featured Solutions

Oncology

-SOPHiA DDM™ for Solid Tumors: SOPHiA DDM™ for Solid Tumors solutions enable advanced, in-house analysis of complex variant classes. The algorithm-powered capabilities of the SOPHiA DDM™ Platform support accurate detection of single nucleotide variants (SNVs), insertions and deletions (Indels) and copy number variations (CNVs), as well as mutational biomarkers.

-SOPHiA DDM™ for Blood Cancers: Solutions include direct access to the SOPHiA DDM™ Platform, a front-end application to upload and analyze genomic sample data. With its user-friendly interface and various cascading filters, users can generate personalized downloadable reports. It offers sufficient storage while keeping patient data safe by applying the highest industry standards of encryption in compliance with local data security policies.

-SOPHiA DDM™ for Hereditary Cancers: SOPHiA DDM™ for Hereditary Cancers gives experts confidence in their results and overcomes challenges associated with analyzing the genes linked to the major hereditary cancer syndromes (i.e., breast and ovarian cancer, Lynch and intestinal polyposis syndromes).

-SOPHiA DDM™ for Liquid Biopsy: Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free DNA, advancing your oncology research to new horizons.

-CE-IVD Oncology Applications: As genomic analyses become standard in both clinical and research settings, professionals are faced with the complex task of translating raw sequencing data into precision medicine approaches. SOPHiA Genetics’ in vitro diagnostic (IVD)-marked genomic applications offer end-to-end workflows that support accurate data analysis and reveal actionable insights, informing data-driven decisions and ultimately improving the quality of patient care.

Rare and Inherited Diseases

-SOPHiA DDM™ for Cardiovascular Diseases: Enhance your variant discovery with advanced analytics and dedicated features. Quickly and accurately detect variants associated with cardiovascular diseases in a single sample-to-report workflow with the SOPHiA DDM™ Platform complemented by Alamut™ Visual Plus.

-SOPHiA DDM™ for Metabolism: The SOPHiA DDM™ Platform offers a streamlined analytical workflow (from FASTQ file to report), thus reducing turnaround time and increasing operational efficiency. Relying on the platform’s high-quality metrics, you can make better-informed decisions for a better care.

– SOPHiA DDM™ for Neurological Disorders: Quickly and accurately detect variants causing neurological disorders by leveraging on the advanced analytical capabilities and dedicated features of the SOPHiA DDM™ Platform complemented by Alamut™ Visual Plus. Streamline your data-driven research decision-making from exome and targeted NGS panels today.

– SOPHiA DDM™ for Pediatric Diseases: Pediatric genetic testing can detect thousands of variants for interpretation. To facilitate the prioritization of variants, benefit from time-saving SOPHiA DDM™ features such as Familial Variant Analysis for the determination of inheritance mode, Virtual Panels, Cascading Filters, and guideline-driven classification.

– SOPHiA DDM™ for Pharmacogenomics: SOPHiA DDM™ Platform supports the accurate detection of Copy Number Variations (CNVs) at exon-level resolution alongside Single Nucleotide Variants (SNVs) and Indels in a single experiment, facilitating a fast and cost-effective workflow for PGx testing.

– SOPHiA DDM™ for Rare Diseases: Mutations in mitochondrial DNA (mtDNA) cause a diverse range of diseases affecting 1 in 5000 people,2 a substantial portion of the rare disease community. NGS of the mitochondrial genome, alongside the exome, can be valuable in rare disease research. In a single workflow, the SOPHiA DDM™ Platform analyzes variants in mtDNA alongside SNVs, Indels, and CNVs in both coding and biologically-relevant non-coding regions of nuclear DNA. The platform’s sophisticated algorithms address the unique challenges associated with the mitochondrial genome such as the variable amount of mtDNA and heteroplasmy, to identify potentially causative variants.

BioPharma

– SOPHiA DDM™ Real-World Data Solutions: Having the right data at the right time can de-risk and accelerate your drug development journey. SOPHiA DDM™ Real-World Data (RWD) Solutions automate patient identification, streamline clinical trial site and biomarker selection, and help you visualize molecular epidemiology and genetic testing insights at a global scale. Supported by a vast clinical research network of 780+ Institutions, the SOPHiA DDM™ Platform allows you to generate data-driven evidence and leverage it to make informed decisions at every step of the process.

– SOPHiA DDM™ Multimodal Analytics Solutions: Transforming multimodal data into powerful predictive insights with decentralized analytics and a global healthcare network. Expert guidance coupled with the machine learning-powered capabilities of the SOPHiA DDM™ Platform enables you to explore unmet medical needs, pinpoint the super-responders and hard-to-treat patients in your clinical studies, streamline trial design and management, and optimize your investments. Don’t let fragmented and unstructured data hinder your clinical research and development programs.

Scroll to Top